Preview of new drugs for overactive bladder and incontinence: darifenacin, solifenacin, trospium, and duloxetine.
This year, the US Food and Drug Administration will approve four new drugs indicated for the treatment of lower urinary tract dysfunction. Darifenacin, solifenacin, and trospium are antimuscarinic agents aimed at relieving the symptoms of overactive bladder and urge incontinence in men and women. Duloxetine will be the first drug approved for the treatment of female stress urinary incontinence. This article presents current data on the efficacy and tolerability of these new agents and invites the reader to decide whether they offer any potential advantages over existing therapies.
Division of Urology, University of Vermont School of Medicine, 1775 Williston Road, South Burlington, VT 05403, USA. richard.kershen@vtmednet.org.
Richard T
RT
Kershen
Mike
M
Hsieh
D001561:Benzilates; D001572:Benzofurans / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D000068736:Duloxetine Hydrochloride; D006801:Humans; D018727:Muscarinic Antagonists / Q000627:therapeutic use*; D009662:Nortropanes / Q000627:therapeutic use*; D011759:Pyrrolidines / Q000627:therapeutic use*; D011812:Quinuclidines / Q000627:therapeutic use*; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use*; D000069464:Solifenacin Succinate; D044005:Tetrahydroisoquinolines / Q000627:therapeutic use*; D013876:Thiophenes / Q000627:therapeutic use*; D014549:Urinary Incontinence / Q000188:drug therapy*
D001561:Benzilates; D001572:Benzofurans; D000068736:Duloxetine Hydrochloride; D018727:Muscarinic Antagonists; D009662:Nortropanes; D011759:Pyrrolidines; D011812:Quinuclidines; D017367:Selective Serotonin Reuptake Inhibitors; D000069464:Solifenacin Succinate; D044005:Tetrahydroisoquinolines; D013876:Thiophenes; C003330:trospium chloride; C101207:darifenacin